Royal Bank of Canada upgraded shares of Consort Medical (LON:CSRT) to a sector performer rating in a research report report published on Monday, Stock Target Advisor reports.
Separately, Shore Capital cut Consort Medical to a hold rating in a report on Monday, November 18th.
Shares of CSRT stock opened at GBX 1,010 ($13.29) on Monday. The stock has a market capitalization of $502.28 million and a PE ratio of 127.85. Consort Medical has a 1-year low of GBX 702 ($9.23) and a 1-year high of GBX 1,075 ($14.14). The business has a 50-day moving average of GBX 1,021.10 and a 200 day moving average of GBX 870.48. The company has a debt-to-equity ratio of 55.58, a current ratio of 1.83 and a quick ratio of 1.16.
About Consort Medical
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products.
Recommended Story: Why do analysts give a neutral rating?
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.